In a report released on October 10, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), ...
AstraZeneca and GlaxoSmithKline produce some of the most widely used inhalers in the United States, including Symbicort and ...
Cerebras is playing in a huge market with insatiable investor demand, but its IPO prospectus is littered with red flags that ...
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
This year's International Symposium on Liver Diseases (IISLD) 2024, held in the San Diego Convention Center, includes two key ...
GlaxoSmithKline Pharma, celebrating 100 years in India, is shifting to a specialty-focused model by entering the oncology ...
New phase 3 results should reopen discussion about the off-label use of COMT inhibitors in early Parkinson's disease, experts ...
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...